Skip to content Skip to footer
Subscribe Now
NEWS

GSK Collaborates with Sino Biopharmaceutical to Accelerate Bepirovirsen at Launch

Shots: GSK has entered an exclusive strategic collaboration with Sino Biopharmaceutical, via its subsidiary CTTQ, to support the launch & commercialization of bepirovirsen (under NMPA’s priority review) in mainland China CTTQ will manage importation, distribution, hospital access, and promotional & non-promotional activities in China under a 5.5yr. supply deal with GSK On the other hand,…
May 11, 2026

Read more

NEWS

Waiv Partners with Daiichi Sankyo to Advance AI-Driven Biomarker Discovery for ADC Program

Shots: Waiv has collaborated with Daiichi Sankyo to lead digital pathology biomarker discovery for an ADC program, leveraging its end-to-end computational pathology platform Waiv will use its platform to analyze early-phase trial data, incl. tumor microenvironment profiling across H&E & IHC slides, biomarker discovery, & outcome prediction, aimed at identifying biomarkers of treatment response The…
May 7, 2026

Read more

NEWS

Guardant Health and Nuvalent Partner on Precision Oncology Diagnostics

Shots: Guardant Health has entered into a multi-year strategic collaboration with Nuvalent to support the development & potential commercialization of Nuvalent’s oncology pipeline using the Guardant Infinity platform The partnership will use Guardant’s tissue & liquid biopsy tests to support Nuvalent’s global clinical studies & evaluate companion diagnostic development for Nuvalent’s investigational cancer therapies The…
May 1, 2026

Read more

NEWS

Huahui Health and BeOne Medicines Partner for HH160 in a ~$2.02B Deal

Shots: Huahui Health has entered into a global exclusive option, license & collaboration agreement, granting BeOne an exclusive option for the development, manufacturing, & commercialization of HH160, a novel trispecific antibody in oncology immunotherapy As per the deal, Huahui will receive $20M upfront, $100M upon exercising the option, & ~$1.9B in development, regulatory & sales milestones, as well as tiered…
April 30, 2026

Read more

NEWS

Profluent Signs ~$2.25B Pact with Eli Lilly to Advance AI-Designed Recombinases for Genetic Medicines

Shots: Profluent has entered into a multi-program strategic research collaboration with Eli Lilly to develop & commercialize custom site-specific recombinases to address diseases with unmet needs As per the deal, Profluent will use its AI models to design & optimize site-specific recombinases for multiple genomic targets, while Lilly will gain exclusive rights to selected assets…
April 29, 2026

Read more

NEWS

Piramal Pharma Solutions Partners with Ajinomoto Bio-Pharma Services to Advance ADC Development and Manufacturing

Shots: Piramal Pharma Solutions has entered into a strategic collaboration with Ajinomoto Bio-Pharma Services to support antibody-drug conjugate (ADC) development and manufacturing programs Under the agreement, Piramal will refer customers to Ajinomoto’s AJICAP platform for site-specific ADC conjugation, while Ajinomoto will direct clients to Piramal for CDMO manufacturing services across development and commercialization The collaboration…
April 17, 2026

Read more

NEWS

Telix Partners with Regeneron to Develop and Commercialize Radiopharmaceutical Therapies for Pain in a ~$2.1B

Shots: Telix and Regeneron have entered into a collaboration to jointly develop and commercialize next-generation radiopharmaceutical therapies Telix will receive a $40M upfront from Regeneron for four initial programs, with options to expand. The companies will share commercialization costs and profits, while Telix may opt to earn up to $535M per program in development and…
April 13, 2026

Read more

NEWS

Haisco Partners with AbbVie to Develop Novel Medicines for Pain in a ~$745M Deal

Shots: Haisco Pharma entered an exclusive licensing deal with AbbVie, granting later global rights (ex-China, Hong Kong & Macau) to develop, manufacture & commercialize novel pain therapies As per the deal, Haisco will receive $30M upfront, with the potential to receive up to $715M in development, regulatory, and commercial milestones, along with tiered royalties on future…
April 13, 2026

Read more

NEWS

Oxford BioTherapeutics Partners with BMS to Develop Next-Generation T-cell Engagers for Solid Tumors

Shots: Oxford BioTherapeutics has entered into a multi-year strategic collaboration with Bristol Myers Squibb (BMS) to discover and develop next-generation T-cell engager therapies targeting solid tumors Under the agreement, OBT will leverage its OGAP-Verify platform to identify tumor-selective targets and design & delivery of developed candidates, while Bristol Myers Squibb will lead subsequent clinical research,…
April 10, 2026

Read more

Load more